NAD+

NAD+ Nasal Spray is supplied by Crystal Peptides as a catalogued research material in this format and strength: nasal spray, 500mg/10ml. The presentation identifies the catalogue product, not a validated experimental application.

NAD+ is the oxidized form of nicotinamide adenine dinucleotide, a dinucleotide coenzyme, not a peptide. It participates in redox chemistry through its relationship with reduced NADH and serves as a substrate in other enzyme-mediated processes. Protonation, counter-ion and hydration state can affect molecular records; the exact supplied chemical form must therefore be established from batch documentation rather than inferred from the product name.

Chemical properties and registry information

Registry information describes a molecular entity, not the complete formulated product. Batch-specific identity records take precedence over general compound identifiers.

Research background and published evidence

Published research

Published NAD+ research includes enzyme-cofactor studies, redox assays, sirtuin research, ADP-ribosylation studies and analytical investigations of nicotinamide nucleotide metabolism. NAD+ may be examined as a substrate, cofactor or analyte, depending on the experimental system. These uses concern defined research materials and assay conditions and do not independently characterize this catalogue formulation.

Current scientific understanding

The biochemical role of NAD+ is distinct from questions about extracellular availability, cellular uptake and intracellular nucleotide pools. Evidence for an enzyme reaction does not by itself demonstrate how an externally supplied formulation behaves in a biological system. NAD+ and NADH also require analytical distinction: findings for one redox state should not be assigned to the other without appropriate measurement.

Formulation note

Published research has mostly used materials or routes other than this nasal spray formulation, including defined laboratory reagents and differently formulated preparations. Findings from injected or differently formulated material cannot be transferred to this nasal spray formulation. Excipients, chemical form and the formulation matrix may influence analytical interpretation. The catalogue strength alone does not establish equivalence to a published preparation, and formulation-specific conclusions require directly relevant evidence.

Quality and testing

Quality documentation must be specific to the nasal spray, 500mg/10ml presentation and the supplied lot. Consult the matching batch-specific CoA for reported identity, analyte content, methods and results, and the SDS for documented composition and material information. A report for another presentation, size or lot is not evidence for this product.

Chromatographic area purity, identity, measured NAD+ content, degradation products, microbiological attributes and elemental impurities are separate analytical questions. One reported result does not establish the others. Only measurements documented in a matching report should be treated as available; unreported attributes must not be inferred from the product name or format.

For laboratory research use only by qualified professionals. Not for human or veterinary use. This catalogue description provides no dosing directions and does not establish suitability for clinical or personal use.